Versant Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Versant Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16	Closed	-$3K	–	1672
2021 Q2	$3K	Sell	16 -21	-57%	-$3.6K	﹤0.01%	1090
2021 Q1	$6K	Buy	37 +6	+19%	+$928	﹤0.01%	992
2020 Q4	$4K	Hold	31	–	–	﹤0.01%	1021
2020 Q3	$3K	Hold	31	–	–	﹤0.01%	1033
2020 Q2	$3K	Hold	31	–	–	﹤0.01%	1022
2020 Q1	$2K	Sell	31 -6	-16%	-$589	﹤0.01%	1078
2019 Q4	$4K	Sell	37 -2	-5%	-$214	﹤0.01%	1040
2019 Q3	$3K	Hold	39	–	–	﹤0.01%	1127
2019 Q2	$5K	Sell	39 -101	-72%	-$13K	﹤0.01%	985
2019 Q1	$18K	Sell	140 -11	-7%	-$1.37K	0.01%	679
2018 Q4	$14K	Hold	151	–	–	0.01%	704
2018 Q3	$20K	Hold	151	–	–	0.01%	653
2018 Q2	$18K	Hold	151	–	–	0.01%	678
2018 Q1	$16K	Sell	151 -14	-8%	-$1.67K	0.01%	728
2017 Q4	$19K	Hold	165	–	–	0.01%	693
2017 Q3	$23K	Sell	165 -17	-9%	-$2.31K	0.01%	545
2017 Q2	$22K	Hold	182	–	–	0.01%	567
2017 Q1	$22K	Hold	182	–	–	0.01%	556
2016 Q4	$22K	Sell	182 -69	-27%	-$8.44K	0.01%	563
2016 Q3	$30K	Sell	251 -6	-2%	-$772	0.02%	433
2016 Q2	$30K	Sell	257 -7	-3%	-$993	0.02%	396
2016 Q1	$36K	Sell	264 -6	-2%	-$881	0.02%	323
2015 Q4	$51K	Buy	+270	New	+$47.2K	0.03%	226

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Versant Capital Management's ALXN Position: Q3 2021 in Review

Versant Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 16 shares — an estimated $3K sold.

Versant Capital Management first reported a position in ALXN in Q4 2015 and held it in 23 quarters. The position peaked at $51K in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Versant Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Versant Capital Management sold 16 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3K.
Versant Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 23 quarters.
Versant Capital Management's Alexion Pharmaceuticals position peaked at $51K in Q4 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Versant Capital Management's 13F filing for Q3 2021, filed 29 Oct 2021.